alexa Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.
Immunology

Immunology

Journal of Clinical & Cellular Immunology

Author(s): Damjanovska L, Thabet MM, Levarth EW, StoekenRijsbergen G, van der Voort EI,

Abstract Share this page

Abstract OBJECTIVES: To evaluates the diagnostic performance of the anti-CCP2, anti-CCP3 and anti-mutated citrullinated vimentin (anti-MCV) tests in differentiating rheumatoid arthritis (RA) from other forms of arthritis in a clinical setting of early arthritis. METHODS: In 917 patients with recent-onset arthritis (566 RA, 351 other diseases) and in 99 healthy controls the anti-MCV, anti-CCP2 and anti- CCP3.1 tests were performed and the test characteristics compared. RESULTS: Comparison of the tests for differentiating RA from other causes of arthritis showed a lower specificity for anti-MCV (82.9\%) than for anti-CCP2 (93.4\%) and anti-CCP3.1 (90.0\%). Similarly, the positive likelihood ratio for anti-MCV was also lower (3.6, compared with 8.7, 5.8 for anti-CCP2 and anti-CCP3.1). The anti-MCV test had a higher sensitivity (62\% vs 56.9\% and 58.1\%, respectively). In psoriatic arthritis, spondyloarthropathy and other arthritis anti-MCV antibodies had a prevalence of 15.2\%, 13.9\% and 19.4\%. CONCLUSION: The diagnostic performance of the anti-MCV test in the differential diagnosis of early arthritis is lower than that of the anti-CCP tests. This article was published in Ann Rheum Dis and referenced in Journal of Clinical & Cellular Immunology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords